Related Experiment Videos
An anti-platelet activating factor antibody and its effects on platelet aggregation
N Tatsumi1, Y Terano, K Hashimoto
1Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Japan.
Osaka City Medical Journal
|November 1, 1993
Summary
Producing antibodies against platelet-activating factor (PAF) was challenging due to its low antigenicity. Researchers successfully generated anti-PAF antibodies using colloidal gold, which effectively inhibited PAF-induced platelet aggregation.
Area of Science:
- Immunology
- Biochemistry
- Pharmacology
Background:
- Platelet-activating factor (PAF) is a low-molecular-weight phospholipid implicated in inflammatory and allergic responses.
- Production of specific antibodies against PAF has been historically difficult due to its poor antigenicity.
Purpose of the Study:
- To develop effective polyclonal and monoclonal antibodies against platelet-activating factor (PAF).
- To characterize the specificity and affinity of the generated anti-PAF antibodies.
- To evaluate the functional capacity of these antibodies in inhibiting PAF-induced platelet aggregation.
Main Methods:
- Utilized colloidal gold nanoparticles as a hapten carrier to enhance the antigenicity of PAF.
- Produced and purified polyclonal and monoclonal antibodies targeting PAF.
- Assessed antibody reactivity against PAF and related analogues (lyso PAF, L-alpha-lysophosphatidyl choline palmitoyl) using binding assays.
- Quantified antibody affinities for PAF and its analogues.
- Investigated the effect of anti-PAF antibodies on PAF-induced platelet aggregation in a dose-dependent manner.
Main Results:
- Successfully generated both polyclonal and monoclonal antibodies against PAF using the colloidal gold-hapten carrier system.
- The generated antibodies demonstrated cross-reactivity with PAF, lyso PAF, and L-alpha-lysophosphatidyl choline palmitoyl, but not with phosphorylcholine chloride.
- Antibody affinities were found to be higher for PAF compared to its analogues, lyso PAF and L-alpha-lysophosphatidyl choline palmitoyl.
- The anti-PAF antibodies significantly suppressed PAF-induced platelet aggregation in a dose-dependent manner.
Conclusions:
- Colloidal gold serves as an effective hapten carrier for producing antibodies against poorly antigenic molecules like PAF.
- The developed anti-PAF antibodies exhibit specific binding and functional activity, capable of inhibiting PAF-mediated platelet aggregation.
- These antibodies represent a valuable tool for further research into the biological roles and therapeutic targeting of the PAF pathway.